We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Found Repeat Deficiencies at Valsartan Manufacturer’s Facility
FDA Found Repeat Deficiencies at Valsartan Manufacturer’s Facility
In another twist in the worldwide recall of the contaminated blood pressure medication, valsartan, the FDA released two Form 483 reports issued to the API’s manufacturer in China after inspections in 2016 and 2017.